Treatment of hmgb1-mediated inflammation

1 . A method of treating high-mobility group box protein B1 (HMGB1)-mediated inflammation in a subject, by administering a therapeutically effective amount of P5779 to a subject in need thereof, wherein P5779 is the tetrapeptide FSSE. 
     
     
         2 . The method of  claim 1 , wherein the HMGB1-mediated inflammation is caused by infection. 
     
     
         3 . The method of  claim 2 , wherein the HMGB1-mediated inflammation is caused by viral infection. 
     
     
         4 . The method of  claim 3 , wherein the HMGB1-mediated inflammation is caused by influenza infection. 
     
     
         5 . The method of  claim 1 , wherein the HMGB1-mediated inflammation is caused by bacterial infection. 
     
     
         6 . The method of  claim 1 , wherein the method does not decrease anti-microbial immune responsiveness. 
     
     
         7 . The method of  claim 1 , wherein the P5779 is administered after the onset of infection. 
     
     
         8 . The method of  claim 3 , further comprising administering an antiviral agent to the subject. 
     
     
         9 . the method of  claim 1 , wherein the HMGB1-mediated inflammation is caused by sterile injury. 
     
     
         10 . The method of  claim 1 , wherein the HMGB1-mediated inflammation is caused by acetaminophen toxicity. 
     
     
         11 . The method of  claim 1 , wherein the subject is human. 
     
     
         12 . The method of  claim 1 , wherein the P5779 is administered in a pharmaceutically acceptable carrier.